Biogen (BIIB) is advancing its immunology pipeline with felzartamab showing strong efficacy in late AMR and potential for durable disease control in IgA nephropathy and PMN. The company also has multiple phase 3 and proof-of-concept studies underway, and its lupus programs are progressing with differentiated mechanisms and endpoints. This information is based on an AI-generated summary of Biogen's Piper Sandler 37th Annual Healthcare Conference Audio Transcript from December 3, 2025.

BIIB

<p>Biogen（BIIB）正在推进其免疫学管线，felzartamab 在晚期抗体介导的排斥反应（AMR）中显示出强大的疗效，并在 IgA 肾病和原发性肾小管间质性肾炎（PMN）中具有持久控制疾病的潜力。该公司还在进行多项三期和概念验证研究，其狼疮项目正在以差异化的机制和终点推进。这些信息基于 AI 生成的 Biogen 在 2025 年 12 月 3 日举行的 Piper Sandler 第 37 届年度医疗保健会议音频记录的总结</p>

BIIB：Felzartamab 和狼疮相关资产在后期试验中取得进展，旨在解决主要未满足的需求